Form 4: Intra-Cellular Therapies Director Exercises Options, Acquires 20,000 Shares

Director Rory B. Riggs exercised options to purchase 20,000 shares of Intra-Cellular Therapies (ITCI) common stock at $18.56 per share on March 20, 2024.

Summary

• On March 20, 2024, Rory B. Riggs, a director of Intra-Cellular Therapies, Inc. (ITCI), exercised options to acquire 20,000 shares of common stock.
• The exercise price was $18.56 per share.
• Following the transaction, Riggs directly owns 99,235 shares of ITCI common stock.
• The options exercised were set to expire on March 21, 2024.
• The options were originally granted on March 21, 2014, and vested in two tranches on January 8, 2015, and January 8, 2016.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction (option exercise) by a director. While it could be seen as a positive signal, it's not necessarily indicative of a major shift in the company's prospects.

Positives

• The director's exercise of options could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. This filing indicates a director's exercise of vested stock options, which is a common occurrence.

Comparison to Industry Standards

• Stock option grants and exercises are standard compensation practices in the pharmaceutical industry, used to align the interests of executives and directors with those of shareholders.
• Comparing the vesting schedule (50% after approximately 9 months, and the remainder after approximately 21 months) to similar companies such as Neurocrine Biosciences or Sage Therapeutics, the vesting schedule is fairly standard.
• The exercise price of $18.56 is relevant in the context of ITCI's historical stock performance; comparing this to the stock's trading range over the past 10 years would provide further context.

Stakeholder Impact

• The transaction has a minor impact on shareholders, as it increases the number of outstanding shares, but the effect is likely negligible given the relatively small number of shares involved.

Key Dates